18F-FPPRGD2

**18F-FPPRGD2** is a radiopharmaceutical agent consisting of a pegylated dimeric arginine-glycine-aspartic acid (RGD) peptide labeled with the radioisotope fluorine-18 via a 2-fluoropropionyl group. It is designed for positron emission tomography (PET) imaging and specifically targets integrin αvβ3, which plays a key role in angiogenesis and tumor cell adhesion to the extracellular matrix. The compound demonstrates high binding affinity for integrin αvβ3, making it useful for non-invasive imaging of tumors that overexpress this receptor, such as brain, breast, lung, and renal cancers. Its primary clinical application has been in monitoring response to antiangiogenic therapies and early assessment of treatment efficacy in oncology patients[1][4][5][7]. The drug was initially developed by Stanford University[2].

Other names

fluorine 18 fpprgd2fluorine18 fpprgd2fluorine-18 fpprgd2peg3-e{c(rgdyk)}2